Safety monitoring of oral iron supplements in pregnant women with anemia: a multi-center observational clinical study

Author:

Liu Chang12,Zhang Qianqian1ORCID,Hui Peiye3,Wang Yan4,Li Guohui5,Cao Guangchao6,Xue Zicheng7,Zhang Jing8,Zhang Heng9,Huang Xin10,Wu Jiyong11,Sun Fusehng12,Yan Meixing13

Affiliation:

1. Ocean University of China, Qingdao, Shandong, China

2. Qingdao University Affiliated Qingdao Women and Children’s Hospital, Qingdao, Shandong, China

3. Weifang Maternal and Child Health Hospital, Weifang, Shandong, China

4. Tengzhou Maternal and Child Health Hospital, Tengzhou, Shandong, China

5. Jinan Maternal and Child Health Hospital, Jinan, Shandong, China

6. Linyi Maternal and Child Health Hospital, Linyi, Shandong, China

7. Zaozhuang Maternal and Child Health Hospital, Zaozhuang, Shandong, China

8. Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China

9. Qingdao Haici Hospital, Qingdao, Shandong, China

10. Shandong Qianfuo Mountain Hospital, Jinan, Shandong, China

11. The Second People’s Hospital of Shandong Province, Jinan, Shandong, China

12. Qingdao Municipal Hospital Group, Qingdao, Shandong, China

13. Qingdao University Affiliated Qingdao Women and Children’s Hospital, No. 217, Liaoyang East Road, North District, Qingdao, Shandong, China

Abstract

Aims:To investigate the safety of oral iron therapy in pregnant women with iron-deficiency anemia (IDA) in the real world.Methods:A retrospective analysis was performed on 1792 pregnant patients with IDA who received oral iron supplements from 12 hospitals in Shandong Province from 1 April to 31 June 2021; follow-up and adverse reactions were recorded. They were divided into six groups according to the treatment drugs.Results:The overall adverse reaction rate was 15.4%, and the main adverse reaction site was the digestive system. The incidence of all kinds of oral iron adverse reactions from high to low in order: compound ferrous sulfate and folic acid tablets (21.88%); iron proteinsuccinylate oral solution (20.90%); ferrous succinate tablets (19.76%); ferrous succinate sustained-release tablets (18.00%); iron polysaccharide complex capsule (12.06%); and iron dextran oral solution (6.94%). It was found that there was a significant difference in the incidence of adverse reactions among the six drugs ( p < 0.05). Pairwise comparison showed that the incidence of adverse reactions was higher in the iron proteinsuccinylate oral solution than that in the iron polysaccharide complex capsule ( p < 0.05). There was no significant difference in the incidence of adverse reactions in different ages ( p > 0.05), but there was a significant difference in the incidence of adverse reactions in different gestational ages ( p < 0.05). In Adverse Drug Reaction (ADR) patients, the adverse reaction result of most patients is recovery or improvement, and there was no serious adverse reaction outcome such as sequela and death.Conclusion:All the adverse reactions of oral iron were mainly gastrointestinal adverse reactions, and no heavy adverse reactions were found. Iron proteinsuccinylate oral solution has a higher incidence of adverse reactions than iron polysaccharide complex capsule. The results showed that oral iron was safer for anemia patients during pregnancy.

Funder

Shandong Pharmaceutical Society

Publisher

SAGE Publications

Subject

Pharmacology (medical)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3